Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of oncology therapies. Its lead product candidate is ivonescimab, a bispecific antibody that combines PD-1 blockade with anti-VEGF effects. The company holds rights to develop and commercialize ivonescimab in the United States, Canada, Europe, Japan, Latin America, the Middle East, and Africa, having licensed the asset from Akeso, Inc. Summit is conducting Phase III clinical trials for ivonescimab in non-small cell lung cancer and colorectal cancer, including the HARMONi, HARMONi-3, HARMONi-7, and HARMONi-GI3 studies. The company submitted a Biologics License Application to the FDA for ivonescimab in combination with chemotherapy for EGFR-mutated non-small cell lung cancer, which was accepted for filing in January 2026.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Biotechnology Homepage smmttx.com
Sector Healthcare IR page smmttx.com/investor-information
Tags
oncology, bispecific antibodies, immunotherapy, non-small cell lung cancer, colorectal cancer, pd-1, vegf, clinical trials, ivonescimab, SMT112, AK112, Akeso Inc., HARMONi, HARMONi-3, HARMONi-7, HARMONi-GI3
Press page —

Metrics

Valuation  
Market cap $ 13.523B
Market cap (USD) $ 13.523B
P/E -15.95
PEG —
P/BV 23.95
P/S —
P/OCF -25.75
P/FCF -25.67
Dividend yield —
Turnover / mcap —
Returns  
ROE -206.1%
ROI -239.3%
ROIC -182.0%
Profit margin —
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 135
Quality score -68.8%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 USD FY 2024 USD FY 2023 USD FY 2022 USD FY 2021 USD FY 2020 USD FY 2019 GBP FY 2017 GBP FY 2016 GBP FY 2015 GBP FY 2014 GBP FY 2013 GBP
Revenue — 0 0 705K 1.809M 860K 583K 25.419M 2.304M — — —
Net profit -1.08B -221.315M -614.928M -78.782M -88.602M -52.7M -22.032M -7.131M -21.371M — -11.363M -6.093M
Free cash flow -323.587M -142.245M -76.888M -42.206M -72.893M -48.532M -15.827M -15.049M 12.06M -17.248M -11.36M -5.906M

Figure FY 2025 USD FY 2024 USD FY 2023 USD FY 2022 USD FY 2021 USD FY 2020 USD FY 2019 GBP FY 2017 GBP FY 2016 GBP FY 2015 GBP FY 2014 GBP FY 2013 GBP
Share price 17.49 17.85 2.61 4.25 2.69 4.7 1.3 8.35 6.89 7.58 — —
Price performance 12m -0.02 5.84 -0.39 0.58 -0.43 1.94 0.39 0.29 -0.26 — — —

Filed figures

Figure Jan 2018 Dec 2018 Jan 2019 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — — — 541,000 331,000 1.46M 349,000 0.00 — —
↳ YoY growth -38.8% +342.3% -76.2% -100.0%
Lease liabilities (USD) — — — 893,000 465,000 2.78M 4.45M 6.1M 7.22M 20.9M
Cash and deposits (USD) 28.5M 12.1M 35.2M 63.8M 66.4M 71.8M 349M 71.4M 105M 225M
Intangible assets (USD) — — — 13.1M 11.5M 10.4M 0.00 0.00 0.00 —
Right-of-use assets (USD) — — — 1.02M 600,000 2.79M 4.18M 5.86M 7.14M 20.6M
Cash flow detail
Operating cash flow (USD) — — -35.1M -20.8M -48.1M -72.6M -41.6M -76.8M -142M -323M
Purchases of property, plant and equipment (USD) — — -157,000 -205,000 -421,000 -306,000 -624,000 -128,000 -139,000 -657,000
Purchases of intangible assets (USD) — — -7,000 -136,000 0.00 — — — — —
Change in receivables (cash effect) (USD) — — -2.47M 5.44M 212,000 -1.14M 975,000 359,000 0.00 —
Change in payables (cash effect) (USD) — — -10,000 -1.31M 1.64M -1.71M -4.13M 2.26M 2.02M 15.3M
Dividends paid (cash effect) (USD) — — 0.00 0.00 0.00 — — — — —
Interest paid (cash effect) (USD) — — — — 0.00 -85,000 -434,000 -10.7M -8.81M 0.00
Income taxes paid (cash effect) (USD) — — -72,000 -63,000 70M -7,000 0.00 -52,000 0.00 0.00
Share-based compensation (USD) — — 6.3M 845,000 1.77M 12.8M 11.9M 14.1M 51M 732M
Operating cash flow before change in receivables (USD) — — -32.6M -26.2M -48.3M -71.4M -42.6M -77.1M -142M —
Free cash flow (OCF - PPE - intangibles) (USD) — — -35.3M -21.1M -48.5M -72.9M -42.2M -76.9M -142M -324M
Income detail
Research and development expense (GBP) 29M — 39.2M 31.2M 53.3M 85.4M 52M 59.5M 151M 538M
↳ 5y CAGR +43.7% +42.7% +58.8%
Total comprehensive income (USD) — — 10.4M -29.1M -51.7M -87M -78.5M -615M -221M -1.08B
Comprehensive income to owners (USD) — — 10.4M -29.1M -51.7M -87M -78.5M -615M -221M -1.08B
Reported Mar 31, 2021 Nov 16, 2020 Mar 31, 2021 Mar 31, 2021 Mar 17, 2022 Mar 17, 2022 Feb 20, 2024 Feb 20, 2024 Feb 24, 2025 Feb 23, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Summit Therapeutics Inc. — Other Events Bull 5 Bear 0 Clinical/regulatory

Other Events.

On November 18, 2026, Summit Therapeutics Inc. issued a press release announcing the planned initiation of the global Phase III HARMONi-10 trial (“HARMONi-10”). HARMONi-10 will evaluate ivonescimab compared with durvalumab as consolidation therapy in patients with locally advanced, unresectable Stage III non-small cell lung cancer who have not experienced disease progression following platinum-based concurrent chemoradiation therapy. Global clinical trial site activations for HARMONi-10 are expected to begin in the fourth quarter of 2026.

A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

Summit Therapeutics Inc. — Other Events Bull 0 Bear 7 Clinical/regulatory

Other Events.

On November 15, 2026, Summit Therapeutics Inc. issued a press release announcing that the U.S. Food and Drug Administration (the “FDA”) has issued a Complete Response Letter (“CRL”) regarding the Biologics License Application (“BLA”) for ivonescimab in combination with platinum-containing chemotherapy for the treatment of patients with locally advanced or metastatic non-small cell lung cancer, who have received prior epidermal growth factor receptor tyrosine kinase inhibitor therapy. The CRL indicates that the BLA cannot be approved in its present form, as the FDA determined that substantial evidence of effectiveness is not established in the absence of a statistically significant overall survival (“OS”) improvement. The FDA indicated that the progression-free survival benefit in the absence of a statistically significant OS benefit does not support a positive benefit-risk profile in support of approval. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

Summit Therapeutics Inc. — Other Events Bull 0 Bear 0 Routine

On November 4, 2026, Summit Therapeutics Inc. (the “Company”) filed a prospectus supplement to its automatic shelf registration statement on Form S-3 (Registration No. 333-296642) with the Securities and Exchange Commission. This Current Report on Form 8-K is being filed for the purpose of filing the opinion of Baker & Hostetler LLP relating to the legality of the issuance the shares of common stock of the Company set forth in the prospectus supplement, which opinion is filed as Exhibit 5.1 hereto.

Prompts

Summit Therapeutics Inc. (ticker SMMT), listed in United States.

Company History

Date Change Detail
Dec 31, 2014 Renamed Summit Corp plc → SUMMIT THERAPEUTICS PLC

ETFs Holding Summit Therapeutics Inc.

ETF Weight in ETF Shares Market value As of
PINK 2.18% 682,491 $ 7.282M Nov 17, 2026
CANC 0.97% 150,035 $ 2.043M Aug 31, 2026
BTAL short -0.31% -59,708 $ -869.946K Jun 30, 2026
MKTN short -0.22% -16,156 $ -235.393K Jun 30, 2026
BMED 0.06% 706 $ 8,344.92 Nov 16, 2026
FTLS short -0.04% -82,035 $ 0.00 Nov 16, 2026
REMC 0.01% 32 $ 466.24 Jun 30, 2026
ENHU 0.01% 84 $ 992.88 Nov 16, 2026
MSSM 0.01% 4,528 $ 61.671K Aug 31, 2026
MSLC 0.00% 1,067 $ 14.533K Aug 31, 2026
DFAU 0.00% 1,045 $ 15.753K Nov 12, 2026
DFUS 0.00% 1,139 $ 17.17K Nov 12, 2026